Zoetis Inc. (NYSE:ZTS) Shares Purchased by Atalanta Sosnoff Capital LLC

Atalanta Sosnoff Capital LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 14.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,305 shares of the company’s stock after buying an additional 8,978 shares during the quarter. Atalanta Sosnoff Capital LLC’s holdings in Zoetis were worth $14,037,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Sound Income Strategies LLC increased its position in shares of Zoetis by 1,069.2% in the 2nd quarter. Sound Income Strategies LLC now owns 152 shares of the company’s stock worth $28,000 after purchasing an additional 139 shares during the last quarter. West Oak Capital LLC bought a new stake in shares of Zoetis in the 3rd quarter worth about $29,000. WealthShield Partners LLC increased its position in shares of Zoetis by 60.2% in the 2nd quarter. WealthShield Partners LLC now owns 165 shares of the company’s stock worth $31,000 after purchasing an additional 62 shares during the last quarter. Key Financial Inc increased its position in shares of Zoetis by 72.2% in the 2nd quarter. Key Financial Inc now owns 167 shares of the company’s stock worth $34,000 after purchasing an additional 70 shares during the last quarter. Finally, Red Door Wealth Management LLC bought a new stake in shares of Zoetis in the 2nd quarter worth about $45,000. Hedge funds and other institutional investors own 89.48% of the company’s stock.

In other news, EVP Heidi C. Chen sold 9,446 shares of the company’s stock in a transaction that occurred on Tuesday, November 9th. The shares were sold at an average price of $220.00, for a total value of $2,078,120.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 1,315 shares of the company’s stock in a transaction that occurred on Tuesday, November 23rd. The stock was sold at an average price of $223.09, for a total transaction of $293,363.35. The disclosure for this sale can be found here. Insiders have sold a total of 31,834 shares of company stock valued at $6,741,997 over the last three months. 0.17% of the stock is currently owned by company insiders.

ZTS has been the subject of several research analyst reports. Morgan Stanley initiated coverage on shares of Zoetis in a research report on Thursday, November 18th. They issued an “overweight” rating and a $264.00 target price for the company. Argus boosted their price objective on shares of Zoetis from $195.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, August 25th. Credit Suisse Group boosted their price objective on shares of Zoetis from $206.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, August 9th. Finally, Barclays boosted their price objective on shares of Zoetis from $235.00 to $240.00 and gave the company an “overweight” rating in a research report on Friday, November 5th. They noted that the move was a valuation call. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average target price of $212.30.

Zoetis stock opened at $223.17 on Thursday. The company has a quick ratio of 3.27, a current ratio of 4.54 and a debt-to-equity ratio of 1.41. The firm has a 50-day moving average price of $207.89 and a two-hundred day moving average price of $197.91. The firm has a market capitalization of $105.59 billion, a price-to-earnings ratio of 53.78, a PEG ratio of 3.33 and a beta of 0.66. Zoetis Inc. has a 52-week low of $141.41 and a 52-week high of $228.89.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 4th. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.15. The firm had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.93 billion. Zoetis had a net margin of 26.02% and a return on equity of 52.17%. Zoetis’s revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.10 EPS. Research analysts expect that Zoetis Inc. will post 4.64 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 1st. Shareholders of record on Friday, October 29th will be paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Thursday, October 28th. Zoetis’s payout ratio is 24.10%.

Zoetis Profile

Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

See Also: What is a Buy-Side Analyst?

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.